In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.

The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more. Comprehensive and cutting-edge, Molecular Targeting in Oncology is an essential reference for those working in the field.

Table of Contents


Section 1 General Strategies for Molecular Targeting in Oncology

Chapter 1 The Cell Cycle: Therapeutic Targeting of Cell Cycle
Regulatory Components and Effector Pathways in Cancer
Chad D. Knights and Richard G. Pestell
Chapter 2 mTOR: Properties and Therapeutics
John B. Easton and Peter J. Houghton

Chapter 3 Ras/Raf/MEK Inhibitors
Joseph A. Sparano

Chapter 4 17AAG: Targeting the Molecular Chaperone Heat Shock Protein 90
Len Neckers and Percy Ivy
Chapter 5 The Cancer Epigenome: Can it be targeted for therapy?
Sam Thiagalingam and Douglas V. Faller


Section 2 Molecular Targeting for Specific Disease Sites

Chapter 6 Molecular targeting in upper gastrointestinal malignancies
Scott Wadler

Chapter 7 Molecular Targeting of Colorectal Cancer: An Idea Whose Time
Has Come
Mark L. Sundermeyer, Alfonso Bellacosa, and Neal J. Meropol

Chapter 8 Molecular Targeting in Hepatocellular Carcinoma
Jonathan D. Schwartz. and Josep M. Llovet

Chapter 9 Molecularly Targeted Therapy in Pancreatic Cancer
Anupama Goel and Peter Kozuch

Chapter 10 Untargeted Use of Targeted Therapy: A Dilemma in Non-Small
Cell Lung Cancer
Cheryl Ho, Angela M. Davies, Primo N. Lara, O. Gautschi, P.C. Mack,
Paul H. Gumerlock and David R. Gandara

Chapter 11 Molecular Targeting in Oncology: Renal Cell Cancer
Olwen Hahn and Walter Stadler

Chapter 12 Targeted Therapies for Prostate Cancer
Elisabeth I. Heath and Michael A. Carducci

Chapter 13 Molecular Targets in Ovarian Cancer and Endometrial Cancer
Nilofer S. Azad, Gisele Sarosy, and Elise C. Kohn

Chapter 14 Targeted Therapy for Breast Cancer
Deena M. Atieh and Linda T. Vahdat

Chapter 15 Melanoma
Akshay Gupta and John M. Kirkwood


Section 3 Classes of Drugs for Molecular Targeting in Oncology

Chapter 16 Antibody Therapy of Cancer
Hossein Borghaei, Liat Binyamin, Igor Astsaturov, and Louis M. Weiner

Chapter 17 Nucleic Acid Therapies for Cancer Treatment
Dan T. Vogl and Alan M. Gewirtz

Chapter 18 Engineering Oncolytic Measles Viruses for Targeted Cancer
Therapy
Takafumi Nakamura and Stephen J. Russell

Chapter 19 Vaccines as Targeted Cancer Therapy
Miguel-Angel Perales, Jedd D. Wolchok and Howard L. Kaufman

Chapter 20 Cytokine based therapy for cancer
Henry B. Koon and Michael B. Atkins

Chapter 21 Cyclooxygenase-2 (Cox-2) as a Target for Cancer Prevention
and Treatment
Monica Bertagnolli, Jaye L. Viner, and Ernest T. Hawk


Section 4 Specific Drugs for Molecular Targeting in Oncology

Chapter 22 Imatinib Mesylate (Gleevec) and the emergence of
chemotherapeutic drug-resistant mutation
Gerald V. Denis

Chapter 23 Development of a Targeted Treatment for Cancer: The Example
of C225 (Cetuximab)
John Mendelsohn

Chapter 24 VEGF Inhibition for Cancer Therapy
Shermini Saini and Herbert Hurwitz

Chapter 25 Somatostatin analogue therapy
Manish C. Champaneria, M.D., Irvin M. Modlin, M.D., Ph.D., D.Sc., Igor
Latich, M.D., Jan Bornschein, Ignat Drozdov, Mark Kidd, Ph.D.



Section 5 Challenges in Molecular Targeting in Oncology

Chapter 26 Patient Selection for Rational Development of Novel
Anticancer Agents
Grace K. Dy and Alex A. Adjei

Chapter 27 Clinical Trial Design with Targeted Agents
Sarita Dubey and Joan H. Schiller

Chapter 28 How to define treatment success or failure if tumors don't
shrink: Consequences for trial design.
JJEM Kitzen, MJA de Jonge, and J Verweij

Chapter 29 Molecular Imaging in Oncology
Lalitha Shankar, Anne Menkens, and Daniel C. Sullivan

Chapter 30 Combinations of Molecular Targeted Therapies - Opportunities
and Challenges
Helen X. Chen and Janet E. Dancey

Chapter 31 Preclinical Development of Molecularly Targeted Agents in
Oncology
Joseph E. Tomaszewski and James H. Doroshow